Oncobesity News Posts
Oprah Winfrey opens up on why her GLP-1 weight loss medication became lifelong choice: ‘If I stop the weight comes back’
Oprah Winfrey opens up about her weight loss journey, GLP-1 medication, and the lessons she learned about obesity, self-blame, and lifelong health management.

Older Americans are quitting GLP-1 weight-loss drugs for 4 key reasons
GLP-1 medications have dominated the weight-loss landscape this year — but some older Americans are reportedly kicking the trend to the curb. A study published

The WHO learned to love ‘anti-obesity’ jabs in 2025. I don’t fully agree, but I get it | Devi Sridhar
While GLP-1 drugs promise an easy fix, our bodies still need what they have always needed: healthy food and regular exercise Prof Devi Sridhar is

Novo and Lilly Cut Prices Of Weight-loss Drugs in China
Novo Nordisk and Eli Lilly are lowering prices of their top-selling obesity drugs Wegovy and Mounjaro in China, according to the Danish drugmaker and Chinese

What to Expect on GLP-1s: Typical Side Effects and Symptoms
If you’re starting a GLP-1 medication or have recently begun treatment, you’re probably wondering what to expect. Maybe you’ve heard stories about intense nausea or

Oprah Winfrey admits she drank 17 shots of tequila in one night before giving up alcohol due to GLP-1
Oprah Winfrey is opening up about her weight-loss journey. During a recent interview with People magazine, the 71-year-old television personality discussed her new book, “Enough,”
Science in 2025: the best of the rest
A review of 2025’s noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.

Could This Potential Move Boost Eli Lilly’s Prospects?
Key Points Eli Lilly is working on the acquisition of a France-based drugmaker. This could allow it to expand its footprint in the immunology market.

Could This Potential Move Boost Eli Lilly’s Prospects?
Everything seems to be going well for Eli Lilly (NYSE: LLY). The company’s shares have soared in recent years thanks to strong clinical progress within
A Look Back at 2025: Progress Towards the Treatment of Aging as a Medical Condition
As 2025 winds to a close, it is time once again to look back at some of the aging and longevity research published in the

Combination therapies for metabolic dysfunction-associated steatohepatitis: challenges and opportunities
Metabolic dysfunction-associated steatohepatitis (MASH) is a multifactorial metabolic liver disease that occurs in the context of obesity, insulin resistance and cardiometabolic comorbidities. Monotherapy targeting single

ADHD Drugs Work Differently? Infant Screen Time; GLP-1 Psychological Side Effects
(MedPage Today) — An imaging study suggested prescription attention deficit hyperactivity disorder (ADHD) drugs may work differently than previously thought by affecting arousal and reward,

New CMS Demo Aims to Increase Access to GLP-1s Under Medicaid and Part D
(MedPage Today) — The Trump administration announced a new demonstration program aimed at easing access to GLP-1 receptor agonists for enrollees in Medicare Part D
Oprah Winfrey opens up on why her GLP-1 weight loss medication became lifelong choice: ‘If I stop the weight comes back’
Oprah Winfrey opens up about her weight loss journey, GLP-1 medication, and the lessons she learned about obesity, self-blame, and lifelong health management.
Oprah Winfrey opens up on why her GLP-1 weight loss medication became lifelong choice: ‘If I stop the weight comes back’
Oprah Winfrey opens up about her weight loss journey, GLP-1 medication, and the lessons she learned about obesity, self-blame, and lifelong health management.
Oprah Winfrey opens up on why her GLP-1 weight loss medication became lifelong choice: ‘If I stop the weight comes back’
Oprah Winfrey opens up about her weight loss journey, GLP-1 medication, and the lessons she learned about obesity, self-blame, and lifelong health management.
Oprah Winfrey opens up on why her GLP-1 weight loss medication became lifelong choice: ‘If I stop the weight comes back’
Oprah Winfrey opens up about her weight loss journey, GLP-1 medication, and the lessons she learned about obesity, self-blame, and lifelong health management.
“Americans always want the f*cking pill,” Dr. Robert Lustig, a metabolic scientist at the University of California-San Francisco said, on why GLP-1 drugs are a Band-Aid and not a solution [Amusing]
[link] [13 comments]
Oprah Winfrey opens up on why her GLP-1 weight loss medication became lifelong choice: ‘If I stop the weight comes back’
Oprah Winfrey opens up about her weight loss journey, GLP-1 medication, and the lessons she learned about obesity, self-blame, and lifelong health management.

2 ideas for a SIPP or ISA in 2026
With markets up significantly, 2025 has likely been a great year for most SIPP and Stocks and Shares ISA investors. But what about next year?

This week’s new Audiobooks
Here are this week’s new releases for the category ‘Audiobooks’. ★ Our Staff Pick ★ Weightless: A Doctor’s Guide to GLP-1 Medications, Sustainable Weight Loss,

This week’s new General books
Here are this week’s new releases for the category ‘General’. ★ Our Staff Pick ★ What’s Your Dream?: Find Your Passion. Love Your Work. Build

This week’s new Kindle ebooks
Here are this week’s new releases for the category ‘Kindle’. ★ Our Staff Pick ★ The Rest of Our Lives: A Novel By Ben Markovits

This week’s books in Medicine
Here are this week’s new releases for the category ‘Medicine’. ★ Our Staff Pick ★ Cases in Simulated Disaster Medicine By Andrew Milsten (Editor), John

Humans Have Grown a ‘Second Stomach’ Just for Desserts, Scientist Says
Logic dictates that we load up our one stomach with one meal, and we’re done. For a few hours, at least. But as many of

GLP-1 psychological side effects: a psychiatrist’s view
As a physician-psychiatrist, I have watched the rise of GLP-1 medications (Ozempic, Wegovy, Mounjaro, Zepbound) with genuine admiration. They are transforming metabolic health, reducing cardiovascular

Oprah Winfrey Says She Briefly Stopped Taking GLP-1 for Weight Loss, Until She Realized It’s a ‘Lifetime Thing’
Oprah Winfrey is opening up about her health. The 71-year-old mogul got candid in a new interview about using a GLP-1 weight loss medication, and

‘Give me a name of one of your biggest customers so I can call them’: Optum CEO, Mark Cuban square off
Mark Cuban, co-founder of Cost Plus Drugs Co., and Optum CEO Patrick Conway, MD, sparred over drug prices, pharmacy benefit managers and a range of

For Oprah Winfrey, a croissant is now just a croissant — not a struggle
Oprah Winfrey says the disappearance of so-called food noise is one of the most amazing effects of her GLP-1 drug. Plus now she can take
Derek Thompson on 2025
I think this was a really bad year for American politics, a mediocre year for the American economy, and an exceptional year for America. In

What to know as first FDA-approved GLP-1 pill for weight loss heads for pharmacies
The FDA has approved the first GLP-1 pill for weight loss and it’s expected in pharmacies in the coming weeks. Dr. Holly Lofton, director of

Heartbreakingly Shortsighted
Trump and his throwback henchmen have set scientific research back for decades. This piece from the Atlantic (gift link) spells it out and it’s just

Oprah Breaks Silence on Her One Unexpected Side-Effect of Popular Weight Loss Drug
Talk show queen Oprah Winfrey, who will be turning 72 in January and will be releasing a new book she co-wrote with obesity expert Dr. Ania M.

Oprah’s Wild Booze Confession: Talk Show Legend, 71, Admits to Downing ’17 Shots in One Night’ Before Weight Loss Drugs Made Her Quit Drinking Alcohol
Oprah Winfrey revealed she used to be able to ‘drink everyone under the table’ before GLP-1’s took away her desire for alcohol.

Medifast New Product Line Planned: Can Innovation Reignite Demand?
Medifast, Inc. MED is strategically transitioning beyond its traditional identity as a weight-loss company toward becoming a broader leader in metabolic health. As part of

HIMS Scales AI-Enabled Care as Platform Depth and Engagement Expand
The renowned health and wellness platform, Hims & Hers Health, Inc. HIMS, has consistently positioned technology and clinical infrastructure at the core of its operating

6 new care and payment models CMS introduced in 2025
CMS introduced several new care and payment models in 2025, many focused on drug pricing, chronic disease management and prevention: 1. CMS published plans Dec.

Can Amgen’s MariTide Take on Leaders in the Obesity Space?
Amgen AMGN is one of the few companies with a late-stage obesity candidate in its pipeline. The company is developing MariTide, an investigational GLP-1/GIP receptor

Obesity efforts dominate dealmaking in 2025
When glucagon-like peptide-1 (GLP-1) receptor agonists entered the market for obesity and overweight indications in recent years, the uptake and enthusiasm drove investor excitement for

Tirzepatide noninferior to dulaglutide for CV outcomes in type 2 diabetes
Tirzepatide is noninferior to dulaglutide with respect to a composite of death from cardiovascular (CV) causes, myocardial infarction, or stroke among patients with type 2 diabetes and atherosclerotic CV disease, according to a study published in the Dec. 18/25 issue of the New England Journal of Medicine.